Is ecnoglutide at 5 mg/mL stable enough for three weeks of multi-withdrawal use?

Concretely: ecnoglutide · 5 mg/mL · three weeks.

I want to know whether there is evidence behind this or only repetition.

I have checked the obvious registries and monographs without success.

Can anyone point me at a primary source, or confirm that there is not one?

three weeks is 21 days and, on a weekly schedule, 3 stopper punctures out of one vial at 5 mg/mL. Set the chemical question aside for a moment, because the puncture count is the one with a convention attached: 21 days is 0.75 times the twenty-eight days conventionally allowed for a preserved multi-dose preparation once it has been entered. Chemically, 5 mg/mL is high enough that adsorption to the glass is a rounding error and low enough that it is not protecting you from anything. What 3 withdrawals do add is 3 opportunities to introduce air, 3 coring events on the same stopper, and a headspace that grows with every draw — none of which show up on a certificate and all of which are avoided by splitting into aliquots at reconstitution.

Start with the sequence, because which pathways are available depends on which residues are present.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Reported and extrapolated stability by condition

Windows for the solid state are chemical; windows for solution are microbiological and usually shorter than the chemical limit.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

The honest answer is that most reported "degradation" is adsorption and dilution error rather than chemistry.

Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

On the detail: light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.

A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.

edited 13 Sept 2025 by Dr_Idris_Coulibaly — added the citation requested in comments

Answering this needs the physical state, since a dry powder is protected from most of these and a solution is protected from none.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Put another way, adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

Sequence determines which pathways apply, so general statements are general.

Sequence decides which pathways are even available. Check the residues.

Aggregation is a physical process and is the one most often caused by handling rather than by time.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.

At dilute concentrations, suspect adsorption before you suspect chemistry.

This is answerable from the chemistry rather than from anecdote, which is unusual and welcome.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

The caveat is that "within specification" and "unchanged" are different claims. A vial can lose a few per cent of content and still be usable for its purpose while no longer matching its certificate.

Cold, dry, dark, still. Those four words cover most of the mitigation.